No Data
No Data
Corcept To Present Late-Breaking Data From Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Platinum-Resistant Ovarian Cancer At ASCO 2025
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
Express News | Diabetes Care Publishes Results From Prevalence Phase of Corcept’s Catalyst Trial in People With Difficult-to-Control Type 2 Diabetes
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Analysts' Top Healthcare Picks: Merus (MRUS), Corcept Therapeutics (CORT)
$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today
Warren Buffed : woah, amazing![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Moomoo MY OP : Let us know in the comments!
With Trump's "reciprocal tariff" news, how would you trade in the coming days?
A) Turn to inverse ETFs
B) Target sectors benefiting from trade tensions
C) Focus on domestic stocks
D) Stick to current strategy
EeNiC9J0KM : Bear market, baby!
I'm riding option A: Inverse ETFs. When markets dive, we thrive. 

不吃鱼 Warren Buffed : congratulations

Warren Buffed 不吃鱼 : thanks bro
View more comments...